People who experience depression following a stroke may face a higher risk of poor health and even death for up to a decade afterward, new research finds.

A study published today in the Journal of Cancer Survivorship found that cancer survivors receiving high-cost immunotherapy treatments were more likely to face financial hardship, leading to increased instances of being unable to afford care and taking fewer medications due to cost.

The research, focusing on Medicare-enrolled patients, investigated the financial challenges faced by cancer survivors, particularly those receiving expensive immunotherapies.

“Although it’s well-known that many cancer patients experience financial hardship due to healthcare costs, there’s not much research available that specifically assesses the financial strain linked to immunotherapy treatments, particularly among Medicare enrollees,” said the study’s senior author Cathy Bradley, PhD, Dean of the Colorado School of Public Health on the University of Colorado Anschutz Medical Campus. “As more therapies are developed and the cost of drugs continues to increase, it’s important to determine if patients, even those who are insured, can afford out-of-pocket costs or if these costs are becoming a barrier to access life-saving treatment.”

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.